Home » Reports » USA Broker Ratings » Valeant Pharmaceuticals Intl Inc 80.2% Potential Upside Now Implied by Nomura

Valeant Pharmaceuticals Intl Inc 80.2% Potential Upside Now Implied by Nomura

Valeant Pharmaceuticals Intl Inc with TICKER NYSE:VRX has had its stock rating noted as ‘Initiated’ with the recommendation being set at ‘BUY’ today by analysts at Nomura. Valeant Pharmaceuticals Intl Inc are listed in the Health Care sector within NYSE. Nomura have set a target price of 290 USD on its stock. This now indicates the analyst believes there is a potential upside of 80.2% from the opening price of 160.94 USD.

Valeant Pharmaceuticals Intl Inc NYSE:VRX has a 50 day moving average of 241.46 USD and a 200 Day Moving Average share price is recorded at 212.49 USD. The 52 week high for the stock is 263.81 USD while the year low share price is currently 111.41 USD. Over the last 30 and 90 trading days the company share price has decreased 89.06 points and decreased 77.03 points respectively. There are currently 408,761,734 shares in issue with the average daily volume traded being 2,897,757. Market capitalisation for NYSE:VRX is $67,139,114,810.00 USD.

 

Valeant Pharmaceuticals Intl Inc NYSE:VRX is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Join us on our new LinkedIn page

Follow us on LinkedIn